This post was originally published on this site
Significant developments in the genomics industry have helped researchers quickly identify SARS-CoV-2. Further technological advances, such as the integration of genome-based tests and extensive research and development (R&D), are expected to drive the genomics industry’s growth. According to a The Expresswire report, the genomics market is expected to grow at a 10,8% CAGR over the next five years. Consequently, both CRSP and ILMN should benefit.
ILMN has gained 47.6% over the past year, while CRSP returned 31.5%. Also, ILMN’s 37.8% gains over the past three months are significantly higher than CRSP’s 10.4% returns. And in terms of their past nine months’ performance, ILMN is the clear winner with 75.5% gains versus CRSP’s 11%.
